Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 7/20 | 0.35 |
| ▸ | CMA1 | P23946 | 7/20 | 0.34 |
| ▸ | CTSG | P08311 | 2/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SI | P14410 | 1/20 | 0.32 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2311613 | 0.93 | MEN1 (0.38) | CTSACMA1CTSGSLC6A2CYP3A4 | |
| SCHEMBL2312681 | 0.90 | SLC6A2 (0.36) | CMA1CTSGSLC6A2GPR84MGAM | |
| SCHEMBL2314034 | 0.90 | GAA (0.40) | CTSACMA1CTSGSLC6A2GPR84 | |
| SCHEMBL2313701 | 0.88 | MGAM (0.43) | CTSACMA1CTSGSLC6A2MGAM | |
| SCHEMBL2314344 | 0.88 | GAA (0.39) | CTSACMA1CTSGSLC6A2MGAM | |
| SCHEMBL2312103 | 0.88 | CTSA (0.36) | CTSACMA1CTSGSLC6A2MGAM | |
| SCHEMBL2311580 | 0.88 | CTSA (0.36) | CTSACMA1CTSGSLC6A2MGAM | |
| SCHEMBL2314336 | 0.88 | GAA (0.39) | CTSACMA1CTSGSLC6A2MGAM | |
| SCHEMBL2309124 | 0.86 | MGAM (0.42) | CTSASLC6A2MGAMGAASI | |
| SCHEMBL2309129 | 0.86 | MGAM (0.42) | CTSASLC6A2MGAMGAASI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150556-B2 | Benzimidazolone chymase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-06 | — | — | US | disclosed |
| EP-2152674-B1 | BENZIMIDAZOLONE CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2011-08-03 | — | — | EP | disclosed |
| US-20100240702-A1 | Benzimidazolone Chymase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240702-A1 | Benzimidazolone Chymase Inhibitors | CMA1, SERPINB1, CPA3 | CTSA 55/4885CMA1 1/4885CTSG 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.